Edwards Lifesciences Corporation Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Edwards Lifesciences Corporation (EW) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$11.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-04
- Edwards Lifesciences Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $0.00.
- Edwards Lifesciences Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was -$12.50M.
- Edwards Lifesciences Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-06-30 was $0.00.
- Edwards Lifesciences Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-03-31 was $1.10M.
- Edwards Lifesciences Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was -$11.40M.
- Edwards Lifesciences Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was -$5.30M.
- Edwards Lifesciences Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$29.90M, a 183.52% decline from fiscal 2022.
- Edwards Lifesciences Corporation fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was $35.80M, a 71.15% decline from fiscal 2021.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$12.50M derived: sum of 2 quarters · filed 2026-02-25 | -$12.50M derived: sum of 3 quarters · filed 2026-08-04 | -$11.40M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | -$12.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$12.50M derived: sum of 2 quarters · filed 2026-08-04 | -$11.40M 10-Q · filed 2025-11-05 | -$11.40M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.10M 10-Q · filed 2026-08-04 | $1.10M derived: sum of 3 quarters · filed 2026-08-04 | $1.10M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | $1.10M 10-Q · filed 2026-05-06 | $1.10M derived: sum of 2 quarters · filed 2026-05-06 | $1.10M derived: sum of 3 quarters · filed 2026-05-06 | $1.10M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | -$5.30M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | -$5.30M 10-Q · filed 2025-11-05 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$5.30M 10-Q · filed 2025-08-06 | |||||
| 2024-03-31 | -$5.30M 10-Q · filed 2025-05-06 | ||||||
| 2023-12-31 | -$29.90M 10-K · filed 2025-02-28 | ||||||
| 2023-06-30 | -$26.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | -$26.20M 10-Q · filed 2023-07-28 | -$26.70M derived: sum of 3 quarters · filed 2023-07-28 | $33.40M derived: sum of 4 quarters · filed 2023-07-28 | |||
| 2023-03-31 | $700.00K 10-Q · filed 2023-04-28 | $200.00K derived: sum of 2 quarters · filed 2023-04-28 | $60.30M derived: sum of 3 quarters · filed 2023-04-28 | $39.40M derived: sum of 4 quarters · filed 2023-07-28 | |||
| 2022-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-13 | $59.60M derived: sum of 2 quarters · filed 2023-02-13 | $38.70M derived: sum of 3 quarters · filed 2023-07-28 | $35.80M 10-K · filed 2023-02-13 | |||
| 2022-09-30 | $60.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $39.20M derived: sum of 2 quarters · filed 2023-07-28 | $36.30M 10-Q · filed 2022-10-28 | $54.40M derived: sum of 4 quarters · filed 2023-07-28 | |||
| 2022-06-30 | -$20.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | -$23.80M 10-Q · filed 2023-07-28 | $23.80M 10-Q · filed 2022-07-29 | -$5.70M derived: sum of 3 quarters · filed 2023-07-28 | -$6.80M derived: sum of 4 quarters · filed 2023-07-28 | ||
| 2022-03-31 | -$2.90M 10-Q · filed 2023-04-28 | $2.90M 10-Q · filed 2022-04-28 | $15.20M derived: sum of 2 quarters · filed 2023-04-28 | $14.10M derived: sum of 3 quarters · filed 2023-04-28 | $116.70M derived: sum of 4 quarters · filed 2023-04-28 | ||
| 2021-12-31 | $18.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-13 | $17.00M derived: sum of 2 quarters · filed 2023-02-13 | $119.60M derived: sum of 3 quarters · filed 2023-02-13 | $124.10M 10-K · filed 2023-02-13 | |||
| 2021-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $101.50M derived: sum of 2 quarters · filed 2022-10-28 | $106.00M 10-Q · filed 2022-10-28 | $100.80M derived: sum of 4 quarters · filed 2022-10-28 | |||
| 2021-06-30 | $102.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $107.10M 10-Q · filed 2022-07-29 | $101.90M derived: sum of 3 quarters · filed 2022-07-29 | $110.90M derived: sum of 4 quarters · filed 2022-07-29 | |||
| 2021-03-31 | $4.50M 10-Q · filed 2022-04-28 | -$700.00K derived: sum of 2 quarters · filed 2022-04-28 | $8.30M derived: sum of 3 quarters · filed 2022-04-28 | -$11.30M derived: sum of 4 quarters · filed 2022-04-28 | |||
| 2020-12-31 | -$5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | $3.80M derived: sum of 2 quarters · filed 2022-02-14 | -$15.80M derived: sum of 3 quarters · filed 2022-02-14 | -$13.60M 10-K · filed 2022-02-14 | |||
| 2020-09-30 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | -$10.60M derived: sum of 2 quarters · filed 2021-10-29 | -$8.40M 10-Q · filed 2021-10-29 | $10.10M derived: sum of 4 quarters · filed 2021-10-29 | |||
| 2020-06-30 | -$19.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | -$17.40M 10-Q · filed 2021-07-30 | $1.10M derived: sum of 3 quarters · filed 2021-07-30 | $3.40M derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2020-03-31 | $2.20M 10-Q · filed 2021-04-28 | $20.70M derived: sum of 2 quarters · filed 2021-04-28 | $23.00M derived: sum of 3 quarters · filed 2021-04-28 | $15.00M derived: sum of 4 quarters · filed 2021-04-28 | |||
| 2019-12-31 | $18.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $20.80M derived: sum of 2 quarters · filed 2021-02-12 | $12.80M derived: sum of 3 quarters · filed 2021-02-12 | $6.10M 10-K · filed 2021-02-12 | |||
| 2019-09-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | -$5.70M derived: sum of 2 quarters · filed 2020-10-26 | -$12.40M 10-Q · filed 2020-10-26 | -$15.00M derived: sum of 4 quarters · filed 2020-10-26 | |||
| 2019-06-30 | -$8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | -$14.70M 10-Q · filed 2020-07-27 | $14.70M 10-Q · filed 2019-07-26 | -$17.30M derived: sum of 3 quarters · filed 2020-07-27 | -$23.70M derived: sum of 4 quarters · filed 2020-07-27 | ||
| 2019-03-31 | -$6.70M 10-Q · filed 2020-04-28 | $6.70M 10-Q · filed 2019-04-26 | -$9.30M derived: sum of 2 quarters · filed 2020-04-28 | -$15.70M derived: sum of 3 quarters · filed 2020-04-28 | -$4.80M derived: sum of 4 quarters · filed 2020-04-28 | ||
| 2018-12-31 | -$2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | -$9.00M derived: sum of 2 quarters · filed 2020-02-14 | $1.90M derived: sum of 3 quarters · filed 2020-02-14 | $5.70M 10-K · filed 2020-02-14 | -$5.70M 10-K · filed 2019-02-15 | ||
| 2018-09-30 | -$6.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $4.50M derived: sum of 2 quarters · filed 2018-10-26 | $8.30M 10-Q · filed 2018-10-26 | -$14.10M derived: sum of 4 quarters · filed 2018-10-26 | |||
| 2018-06-30 | $10.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-27 | $14.70M 10-Q · filed 2018-07-27 | -$7.70M derived: sum of 3 quarters · filed 2018-07-27 | $9.00M derived: sum of 4 quarters · filed 2018-07-27 | |||
| 2018-03-31 | $3.80M 10-Q · filed 2018-04-27 | -$18.60M derived: sum of 2 quarters · filed 2018-04-27 | -$1.90M derived: sum of 3 quarters · filed 2018-04-27 | -$5.00M derived: sum of 4 quarters · filed 2018-04-27 | |||
| 2017-12-31 | -$22.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | -$5.70M derived: sum of 2 quarters · filed 2018-02-16 | -$8.80M derived: sum of 3 quarters · filed 2018-02-16 | -$9.90M 10-K · filed 2018-02-16 | |||
| 2017-09-30 | $16.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-27 | $13.60M derived: sum of 2 quarters · filed 2017-10-27 | $12.50M 10-Q · filed 2017-10-27 | $14.70M derived: sum of 4 quarters · filed 2017-10-27 | |||
| 2017-06-30 | -$3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$4.20M 10-Q · filed 2017-07-28 | -$2.00M derived: sum of 3 quarters · filed 2017-07-28 | -$2.10M derived: sum of 4 quarters · filed 2017-07-28 | |||
| 2017-03-31 | -$1.10M 10-Q · filed 2017-04-28 | $1.10M derived: sum of 2 quarters · filed 2017-04-28 | $1.00M derived: sum of 3 quarters · filed 2017-04-28 | $600.00K derived: sum of 4 quarters · filed 2017-04-28 | |||
| 2016-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $2.10M derived: sum of 2 quarters · filed 2017-02-17 | $1.70M derived: sum of 3 quarters · filed 2017-02-17 | $1.10M 10-K · filed 2017-02-17 | |||
| 2016-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-28 | -$500.00K derived: sum of 2 quarters · filed 2016-10-28 | -$1.10M 10-Q · filed 2016-10-28 | ||||
| 2016-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-29 | -$1.00M 10-Q · filed 2016-07-29 | |||||
| 2016-03-31 | -$600.00K 10-Q · filed 2016-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |